Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 13/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | NOS3 | P29474 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL919003 | 1.00 | NOS1 (0.51) | NOS1NOS3NOS2DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL954680 | 1.00 | NOS1 (0.51) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL919004 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1952051 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL6224216 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL4425446 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1952544 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| SCHEMBL1841059 | 0.98 | NOS1 (0.53) | NOS1NOS3NOS2DPP4DPP8 | |
| Acetic Acid SCHEMBL9342261 | 0.93 | NOS1 (0.49) | NOS1NOS3NOS2DPP4DPP8 | |
| Leucine SCHEMBL29264283 | 0.84 | SLC7A5 (0.53) | NOS1NOS3NOS2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110269858-B | Twin medicine for treating ischemic stroke and preparation method thereof | 贵州医科大学 | 2021-07-09 | — | — | CN | claimed |
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-119841841-A | Cycloicaritin carbamate prodrug and salt thereof | 沈阳药科大学 | 2025-04-18 | — | — | CN | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024254404-A2 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | 280 BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-119101070-A | Nitrogen-containing heterocyclic compound, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| CN-118459447-A | Scutellarin aglycone-7-amino carbamate-4' -substituted aminopropyl ether derivative and preparation and application thereof | 贵州医科大学 | 2024-08-09 | — | — | CN | disclosed |
| WO-2004037162-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6706729-B1 | A METHOD FOR DISSOCIATING A METAL ION FROM A ZINC FINGER-CONTAINING PROTEIN; INHIBITING VIRUS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-16 | — | — | US | disclosed |
| US-20030219893-A1 | Compositions and methods for the treatment of hepatitis C virus infection | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2003-11-27 | — | — | US | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-6472410-B1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1087941-A2 | THIOLESTERS AND USES THEREOF | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065871-A2 | THIOLESTERS AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | DPP4 981/4885NOS1 2845/4885NOS3 4048/4885 |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | DPP4 348/4885NOS1 1530/4885NOS3 1338/4885 |
| US-20240425512-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | KRAS, NRAS, HRAS | DPP4 4139/4885NOS1 407/4885NOS3 465/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | DPP4 1781/4885NOS1 261/4885NOS3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.